Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits

Hyperglycemia is an undisputed epidemiological risk factor for microvascular complications in both type 1 and type 2 diabetes, integral in their causal pathways. Importantly, interventions that reduce the hyperglycemic burden in patients with either type of diabetes reduce the risk of microvascular...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuire, Darren K., Inzucchi, Silvio E., Johansen, Odd Erik, Rosenstock, Julio, George, Jyothis T., Marx, Nikolaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048355/
https://www.ncbi.nlm.nih.gov/pubmed/33858511
http://dx.doi.org/10.1186/s40545-020-00295-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048355/
https://www.ncbi.nlm.nih.gov/pubmed/33858511
http://dx.doi.org/10.1186/s40545-020-00295-3

Ejemplares similares